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Abstract: Primary cardiac sarcomas are rare and represent 20% of
all primary cardiac tumors. Symptoms depend on the chambers and
the cardiac structures involved. Transthoracic echocardiography is
commonly used to identify a cardiac mass. The diagnosis of cardiac
sarcoma requires adequate sampling and the careful use of ancillary
diagnostic techniques. In the most recent histologic classification,
angiosarcoma is the most common malignant tumor of the heart with
recognizable differentiation. Undifferentiated sarcomas account for
one-third of all cardiac sarcomas and have been incorporated in the
malignant fibrous histiocytoma/pleomorphic sarcoma subgroup.
Elective cardiac sarcoma therapy includes complete surgical exci-
sion when possible, followed by radio and chemotherapeutic regi-
men, the latter preferably containing anthracyclines, ifosfamide, or
taxanes. Prognosis of cardiac sarcomas is very poor, with mean
survival ranging from 9.6 to 16.5 months. A less-aggressive course
seems related to the left atrium location, a low histologic grading
with scarce cellular pleomorphism and low-mitotic activity, absence
of necrosis, myxoid tumor appearance, and absence of metastasis at
diagnosis.
Key Words: Tumors of the heart, Classification, Diagnosis, Ther-
apy, Pleomorphic sarcoma, Angiosarcoma.
(J Thorac Oncol. 2010;5: 1483–1489)
Primary cardiac sarcomas are malignant neoplasms deriv-ing from mesenchymal cells and confined to the heart at
the time of diagnosis. Most cardiac sarcomas have the same
histologic appearance similar to their soft tissue counterpart.
Consequently, an extremely rare metastasis from a preexist-
ing noncardiac sarcoma should be excluded. Nevertheless,
primary heart sarcomas are exceptionally rare. In a large
study by the American Medical Association, prevalence of
primary cardiac sarcomas at autopsy was 0.0017%,1 with an
incidence from 0.001 to 0.030%2 and a general incidence of
0.07%.3 Cardiac metastases at autopsy occur 20 to 40 times
more frequently than primary neoplasms4 and originate
mainly from cutaneous melanoma, lung, and breast carcino-
mas. Sarcomas represent approximately 10 to 20% of total
primary cardiac tumors5,6 and occur without any gender
predilection. Cardiac sarcomas may arise in any area of the
heart, although angiosarcoma is typically found in the right
atrium,7 whereas fibrosarcoma and undifferentiated sarcoma
in the left atrium.5,8 Transthoracic echocardiography is the
most common method of instrumental investigation.9 Elec-
tive therapy includes complete surgical excision when possi-
ble, followed by radio- and chemotherapy. Despite these
therapeutic strategies, prognosis of cardiac sarcomas is very
poor, with median survival of less than 1 year.10
CLASSIFICATION
For many years, no universally accepted classification
of primary cardiac sarcomas existed. The difficulty derived
from the rarity and lack of systematic studies, with only a few
series of cardiac sarcomas reported in the literature. Virtually,
all soft tissue sarcoma types have also been found to arise in
the heart. However, it remains difficult to apply the same
histologic classification, because most cardiac sarcomas have
limited areas with morphologically recognizable differentia-
tion. Moreover, despite a careful immunohistochemical
study, they frequently lack tissue-specific antigens. The re-
cent World Health Organization classification system of car-
diac tumors proposed in 200411 is largely based on the soft
tissue classification counterpart and only the most frequent
malignant entities are listed (Table 1). Major changes compared
with previously reported classification include the incorporation
of undifferentiated sarcoma, previously considered a separate
entity,5 in the malignant fibrous histiocytoma (MFH)/undiffer-
entiated pleomorphic sarcoma subtype. Moreover, malignant
mesenchymoma, a sarcoma showing two or more lines of
differentiation, is no longer mentioned. In accordance with
the soft tissue tumors classification, malignant mesenchymo-
mas would nowadays be recognized as examples of other
better defined malignant tumors, such as dedifferentiated
liposarcoma, malignant peripheral nerve sheath tumor, or
undifferentiated pleomorphic sarcoma displaying heterolo-
gous elements.12 Undifferentiated sarcomas and angiosar-
coma are the most frequent primary malignant tumors of the
heart, accounting for up to 66% of all sarcomas in the two
large series published in 19965 and 2004.11 MFH/undifferen-
tiated pleomorphic sarcoma accounts for more than one-third
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of all malignant tumors of the heart11 but only 5% of all cases
are soft tissue tumors.12 In the 2004 World Health Organiza-
tion classification of cardiac sarcomas, exceptionally rare
entities such as chondrosarcoma and osteosarcoma are no
longer mentioned. A histologic revision of the few described
cases of cardiac chondrosarcoma revealed the paucity of this
finding and the presence of other better morphologically
defined sarcomas.11 Osteosarcomas of the heart are preferably
reported as cases of undifferentiated pleomorphic sarcomas
with prominent osteosarcomatous differentiation.11 Finally,
myxofibrosarcoma has been classified as a myxoid variant of
fibrosarcoma.11
Histogenesis and Genetic Features of
Cardiac Sarcomas
The classic histogenetic hypothesis presumed that
most cardiac sarcomas derive from a pluripotential mes-
enchymal cell.5 At present, molecular histogenesis of car-
diac sarcomas is poorly known, and there are no specific
genetic mutations reported. This is likely due to the rarity
and consequent absence of a systematically characterized
large series of cardiac sarcomas. K-ras mutation and the
absence of p53 mutations have been reported in three cases
of angiosarcomas and two cases of rhabdomyosarcomas of
the heart.13 Naka et al.14 reported p53 mutations in two
primary cardiac angiosarcomas. Finally, synovial sarco-
mas typically harbor t(X; 18; p21.2;q11.2) resulting
mainly in SS18-SSX1 fusion transcripts, included in the
examined case of cardiac localization.15
Clinical Presentation
Cardiac sarcomas may arise at any age without gender
predominance. Reported mean age at clinical presentation is
41 years.8 At diagnosis, most patients are symptomatic and
two-third in class III/IV of the New York Health Association
functional classification system for staging heart failure. One-
third of patients with primary cardiac sarcomas show metas-
tasis at diagnosis.16 Symptoms depend on the cardiac struc-
tures or chambers involved in tumor growth. Dyspnoea and
orthopnoea from pulmonary venous hypertension and frank
pulmonary edema are the most common symptoms; systemic
embolization is also quite frequent.17 Other symptoms in-
clude fever, arrhythmias, chest pain, pericardial tamponade,
and congestive heart failure. Although found in all chambers
of the heart, 50% of cardiac sarcomas are located in the left
atrium, in particular, 75% of leiomyosarcomas18 and 81% of
undifferentiated pleomorphic sarcomas.19 Rare previously
reported cardiac osteosarcomas20 and malignant mesenchy-
moma21 were also invariably observed to origin within the
left atrium. Exceptionally, rare biatrial involvement from
undifferentiated sarcomas has been reported.22 For all these
tumors, dyspnoea is the most common symptom. Angiosar-
coma is typically observed in the right atrium of male
patients7,23 and symptoms include dyspnoea, pulmonary
edema, liver and spleen enlargement, and ascitis. Because of
the propensity of cardiac angiosarcoma to invasion, pericar-
dial constriction and cardiac tamponade are frequent, and
lung, bone, liver, and spleen metastasis is reported7; malig-
nant pericardial effusion can be the first clinical evidence of
a cardiac sarcoma.24 Rhabdomyosarcoma may arise through-
out the entire myocardium, mostly in male children.25 Finally,
liposarcoma may involve both atria.26
Imaging
Most cardiac sarcomas are diagnosed by transthoracic
echocardiography, eventually followed by a presurgical
transesophageal echocardiography.10,27 The presence of inva-
sion and metastasis is documented by total body computed
tomography (CT) and magnetic resonance imaging (MRI).
These techniques provide useful information on tumor size
and localization and involvement of cardiac anatomic struc-
tures, with particular reference to valves. MRI after contrast
enhancement allows three-dimensional high-resolution to-
mography of the thoracic cavity including mediastinum, lung
and large vessels, and tumor invasion of pericardic, intramu-
ral or intracavitary space can be distinguished. Finally, MRI
better defines the lipomatous, myxoid, and thrombotic com-
position of an intracardiac mass.28,29 Coronary angiography is
performed in patients with symptoms of coronary artery
disease and/or possible coronary involvement by a cardiac
mass. The combination of echocardiography, CT, or MRI
generally provides an excellent anatomic definition for pre-
operative planning.
Histopathologic Diagnosis
An exhaustive sampling of a surgical specimen clini-
cally suspected to be a cardiac sarcoma is needed to reach the
correct diagnosis and grading. All areas that appear macro-
scopically heterogeneous (i.e., solid, myxoid, hemorrhagic,
and necrotic areas) should be sampled and microscopically
examined. If necessary, ultrastructural examination can be
performed. Microscopic evaluation helps to recognize impor-
tant diagnostic features, such as architectural (storiform, her-
ringbone, whirling, or diffuse), cellular (spindle, small, large,
and pleomorphic cells), and microvasculature pattern (curvi-
linear, hyaline, or chicken wire), the presence of stromal
reaction (myxoid or sclerotic), hemorrhage, and necrosis if
surgical resection was not preceded by therapeutic regimens
(see later). At higher magnification, cytologic atypia and
specific differentiation (i.e., the presence of rhabdomyoblasts,
pseudolipoblasts, or blunt-ended cigar-shaped nuclei) should
be recognized. It is worth noting that primary cardiac tumors
can be polymorphic with heterogeneous areas of differentia-
tion. Finally, a careful immunohistochemical study is useful












Modified from cardiac sarcoma classification in “tumors of lung, heart and peri-
cardium,” edited by WHO in 2004.
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to reach a correct diagnosis and grading, in particular, of
differentiated cardiac sarcomas. A panel of main immunohis-
tochemical reactivity is schematically reported in Table 2.
Angiosarcoma
Angiosarcoma is typically found in the right atrium.7,30
Macroscopically, angiosarcoma appears as a gray-brown
mass with hemorrhagic areas (Figures 1A, B). In two-third of
cases, angiosarcoma is microscopically characterized by vas-
cular differentiation with channels covered by endothelial
cells exhibiting marked atypia (Figure 1C); endothelial pap-
illary structures can be also observed. Solid areas of spindle
or epithelioid cells with vacuoles containing erythrocytes can
be detected (Figure 1D). Atypia and mitosis are fundamental
in the differential diagnosis with other tumors sharing a
vascular differentiation, such as hemangioma and heman-
gioendothelioma. In some cases, angiosarcomatous areas
with spindle cell pattern must be differentiated from those
present in fibrosarcoma, MFH, and Kaposi sarcoma. The
latter can involve the heart, as reported in 17 to 19% of
classic, endemic, and AIDS-related cases.31 Immunodetection
of factor VIII or CD34 positive neoplastic cells represents
useful markers of endothelial differentiation; moreover, cy-
tokeratins can be diffusely positive in epithelioid areas of
angiosarcoma.32
Unclassified Sarcoma/Pleomorphic MFH
A cardiac sarcoma with no specific histologic pattern is
classified as undifferentiated.5 Nowadays, undifferentiated
sarcoma is considered synonymous with pleomorphic
MFH.11,12 Undifferentiated sarcomas have previously been
distinct in pleomorphic, epithelioid ,or small-cell subtypes.5
Macroscopically, MFH appears yellowish-white with areas of
necrosis and widely infiltrating myocardium and cardiac
structures (Figures 2A, B). Microscopically, unclassified sar-
coma/pleomorphic MFH displays great heterogeneity in ap-
pearance and variable cellularity, with alternated areas of
spindled and epithelioid cells, sometimes with abundant eo-
sinophilic cytoplasm and intermixed giant cells (Figures 2C,
D). The presence of storiform arrangement, marked pleomor-
phism, high mitotic activity, and foci of necrosis is commonly
reported. In some cases, undifferentiated sarcomas are char-
acterized by the presence of small cells (Figure 2E) with
phenotypical and ultrastructural features of embryonal or
primordial mesenchymal cells and no further recognizable
differentiation.22 Chondromatous differentiation in MFH/ple-
omorphic sarcoma can also be detected (Figure 2F), but the
term chondrosarcoma is no longer reported in the classifica-
tion of cardiac sarcomas and a diagnosis of MFH/pleomor-
phic sarcoma with heterologous elements is preferable. Nev-
ertheless, the recognition of mature cartilaginous tissue in a
cardiac tumor is diagnostic of malignancy.11 The finding of
true primitive osteosarcomas of the heart is debated. When
osteosarcomatous areas are present, the diagnosis of MFH/
pleomorphic sarcoma with osseous differentiation is pre-
ferred.11 Undifferentiated sarcoma must be distinguished
from embryonal rhabdomyosarcoma and metastatic small cell
cancer. Immunostaining is crucial, being epithelial, neural, or
endothelial markers are usually negative and vimentin typi-
cally positive; high-grade undifferentiated sarcomas can ex-
hibit focal -smooth muscle positive areas, but the latter are
generally limited in their extension.32
FIGURE 1. A, Example of cardiac angiosarcoma; (B) mac-
roscopically, cut surface appears reddish-brown from al-
ternating solid and hemorrhagic areas. Microscopically,
the tumor shows (C) well-differentiated areas with vascu-
lar channel lined by atypical endothelial cells, and (D)
solid areas from accumulation of large epithelioid cells
with marked pleomorphism, mitosis (arrow) and atypical
cells with vacuolized cytoplasm containing erythrocytes
(*) (Hematoxylin and Eosin).
TABLE 2. Immunohistochemical Panel of Main Antibodies for the Diagnosis of Cardiac Sarcomas
CD34 FVIII CD31 S100 -SMA Desmin CK Vim Myo
Angiosarcoma       Ra  
Undifferentiated pleomorphic sarcoma     R  R  
Rhabdomyosarcoma         
Fibrosarcoma     R    
Leiomyosarcoma       R  
Synovial sarcoma     R    
Liposarcoma         
a Diffusely positive in epithelioid variant.
FVIII, factor VIII; -SMA, -smooth muscle actin; CK, cytokeratins; Myo, myogenin; Vim, vimentin; R, rare and focal; , positive; , negative.
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Leiomyosarcoma
Leiomyosarcoma is a malignant tumor showing pheno-
typic and ultrastructural smooth muscle differentiation. It has
been described in all cardiac chambers. When located in the
left atrium, it can mimic myxosarcoma.33 Leiomyosarcoma is
microscopically characterized by the presence of a bundle of
atypical spindle cells with characteristic blunt-ended or “ci-
gar-shaped” nuclei (Figures 3A, B) and often Periodic Acid-
Schiff-positive intracytoplasmic vacuoles. Pleomorphic ar-
eas, necrosis, and multinucleated cells may be encountered.
Immunostaining for desmin and smooth muscle actin are
usually diffusely positive (Figures 3C, D), whereas epithelial,
vascular, and neural markers are negative.34
Fibrosarcoma and Myxosarcoma
Fibrosarcoma by definition is microscopically com-
posed of atypical elongated fibroblast-like cells with inter-
spersed collagen and the classic herringbone pattern.11 Fibro-
sarcoma is frequently located in the left atrium, mainly in
young-adult women.8 Myxofibrosarcoma, previously consid-
ered a myxoid variant of MFH, has now been moved to the
fibroblastic categories11,12 and considered a variant of fibro-
sarcoma. Myxofibrosarcoma is characterized by a broad spec-
trum of microscopic appearance, with hypocellular areas with
spindle hyperchromatic cells, abundant myxoid matrix (Fig-
ure 4A), prominent elongated, curvilinear thin-walled blood
vessels (Figure 4B) alternated with hypercellular areas, show-
ing a herringbone growth pattern (Figure 4C), similar to
classic fibrosarcoma. When hypocellular myxoid areas are
diffuse, differential diagnosis with cardiac myxoma can be
difficult. An exhaustive examination is needed to recognize
the presence of areas with nuclear atypia and mitosis. The
absence of typical myxomatous “ring structures” is also
requested for a correct diagnosis of myxosarcoma.
Recently, a presumed primary cardiac low-grade fibro-
myxoid sarcoma has been reported.35 This is a rare tumor
arising in the soft tissue of proximal extremities, trunk, and
thoracic cavity. Because low-grade fibromyxoid sarcoma
seems to have a more favorable course compared with classic
fibrosarcoma, it must be included in its differential diagnosis.
Rhabdomyosarcoma
By definition, a malignant tumor showing striated mus-
cle differentiation is classified as rhabdomyosarcoma.11 It
usually arises in the ventricular wall,8 rarely in the myocar-
dium of the left atrium.36 Unlike the extracardiac counterpart,
primary cardiac rhabdomyosarcoma is almost always of em-
bryonal type and occurs in children or young people. Rhab-
domyosarcoma is microscopically composed of small cells
with the presence of recognizable rhabdomyoblasts. Mas-
son’s trichrome revealing the characteristic cell cross-stria-
FIGURE 2. A, Two-dimensional echocardiography reveals a
large undifferentiated pleomorphic sarcoma/MFH (*) occu-
pying the right ventricle (RV). B, Autoptic examination of the
heart of the patient shows a white-yellowish mass with areas
of necrosis (*) widely infiltrating the myocardium and the
interventricular septum (IVS). C and D, Histologically, the
undifferentiated pleomorphic sarcoma/MFH is constituted by
highly pleomorphic spindle or ephiteliod cells with abundant
eosinophilic cytoplasm and interspersed giant or multinucle-
ated cells (arrows) arranged in vaguely storiform fashion. E,
Undifferentiated pleomorphic sarcoma/MFH, small-cell sub-
type. F, Undifferentiated pleomorphic sarcoma/MFH with
areas of chondroid differentiation (**) (Hematoxylin and Eo-
sin). LA, left atrium; LV, left ventricle; RA, right atrium; MFH,
malignant fibrous histiocytoma.
FIGURE 3. A and B, An example of cardiac leiomyosar-
coma, microscopically composed of variably oriented bun-
dles of pleomorphic spindle cells with blunt-ended nuclei
(Hematoxylin and Eosin). Immunohistochemistry reveals the
presence of diffuse (C) -smooth muscle actin and (D)
desmin-positive cells.
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tions and a diffuse desmin-positive immunostaining help for
a correct diagnosis.8,36 Rhabdomyosarcoma can express other
muscle markers, including myogenin, myoD1, sarcomeric
actin, muscle-specific actin, and myoglobin.37 Among these,
myogenin and myoD1 seem to be more specific.38
Synovial Sarcoma
Synovial sarcoma is a biphasic malignant tumor usually
located in the atria or pericardial surface. The latter localiza-
tion should be considered for distinction from malignant
mesothelioma. In the heart, the monophasic variant of syno-
vial sarcoma is more common. A differential diagnosis be-
tween malignant mesothelioma and synovial sarcoma may be
challenging on the basis of morphologic aspect and immu-
nophenotype, both being positive for cytokeratins, calretinin,
and vimentin. Nevertheless, distinction may be reached con-
sidering that malignant mesothelioma does not occur in the
atria and generally infiltrates the heart, whereas synovial
sarcoma usually seems localized as a rather circumscribed
mass.11 Synovial sarcoma must also be differentiated from
solitary fibrous tumor, which usually expresses CD34. Syno-
vial sarcoma typically harbors t(X; 18; p21.2;q11.2) resulting
mainly in SS18-SSX1 fusion transcripts.15 This cytogenetic
feature represents a useful diagnostic tool and can be detected
by using reverse-transcription polymerase chain reaction or
fluorescence in situ hybridization techniques.
Grading
As for their soft tissue counterpart, histologic grading
of malignancy of cardiac sarcomas has the greatest correla-
tion with survival,39 with the important exception of angio-
sarcoma. Although two-third of cases of cardiac angiosar-
coma display a variable evidence of vascular differentiation
with well-formed vascular channels and papillary structures,
this tumor is highly invasive, with a mean survival of few
months.11 The French Federation Nationale des Centres de
Lutte Contre le Cancer (FNCLCC) classification is the
grading system that seems to better correlate with survival
of soft tissue sarcomas. The FNCLCC system score (grade
1–3) is obtained by evaluating three main histologic pa-
rameters of the tumor (i.e., differentiation, mitotic rate,
and percentage of necrosis).40 The FNCLCC grading is
applicable for untreated sarcomas and requires an exhaus-
tive postsurgical tissue sampling.
Therapy and Prognosis
The gold standard therapy for eligible patients with
cardiac sarcoma without metastasis at diagnosis is a complete
surgical removal of the tumor. Patients undergo operation by
way of median sternotomy with minimal touch technique and
cardiopulmonary bypass under cardioplegic arrest.41 Unfor-
tunately, a complete surgical resection is often complicated
because of the diffuse invasion of cardiac structures, or
almost impossible for tumor localization in those anatomic
sites that require extremely complex reconstruction. Pericar-
dial patches are used to replace removed atrial wall or large
vessel segments, and sometimes valve replacement is also
required.41–43 If complete surgical resection of cardiac sar-
coma is impossible, more than 90% of patients die within 1
year despite any postsurgical therapy.44 When extracardiac
metastasis is identified, surgical resection is reserved for
palliative indication. In a series of 34 cases from Mayo
Clinic, median overall survival was 17 months for patients
undergoing complete surgical excision and 6 months for
those in whom complete tumor removal could not be per-
formed, and the difference was statistically significant.45
Finally, cardiac transplantation can be also considered, be-
cause evidence of long-term benefit in selected patients has
been reported.46,47
There is no general agreement on efficacy of postsur-
gical therapy for cardiac sarcomas. Chemotherapy after sur-
gical resection is recommended, even when clear surgical
margins are obtained because of the high probability of
missed microscopic disease and likely aggressive course.42
Other authors did not find any evidence supporting adjuvant
chemotherapy as beneficial.48 Because there is an absence of
specific clinical trials due to the rarity of the localization for
eligible patients, chemotherapy protocols are derived from
extracardiac soft tissue counterpart data. The most common
regimen for soft tissue sarcoma treatment is combined doxo-
rubicin and ifosfamide but anthracycline chemotherapy is
both cardiotoxic and a radiation sensitizer.49 Nevertheless, an
initial large meta-analysis of adjuvant chemotherapy trials
has shown no survival benefit of adjuvant chemotherapy for
adult soft tissue sarcomas.50 Recently, gemcitabine activity in
soft tissue sarcomas has been described.51 Gemcitabine and
docetaxel in a schedule-dependent combination provided
promising results in patients with leiomyosarcoma52 and with
other soft tissue sarcomas.53 Weekly paclitaxel has been
shown to be highly effective in angiosarcomas, with reported
FIGURE 4. An example of cardiac myxosarcoma, micro-
scopically characterized by (A) prominent elongated, curvi-
linear thin-walled blood vessels and (B) hypocellular areas
with spindle hyperchromatic cells embedded in abundant
myxoid matrix; (C) in other areas, myxosarcoma seems hy-
percellular with herringbone-like growth pattern (Hematoxy-
lin and Eosin). D, Ultrastructural features of a myxosarcoma-
tous cell, with scarce cytoplasm, prominent nucleoli, and
collagen bundles intimately associated to the plasmalemma
(transmission electron microscopy).
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overall tumor control rate of 70%.54 Nakamura-Horigome et
al.55 reported the case of a 49-year-old man with a primary
cardiac angiosarcoma of the right atrium and cardiac tampon-
ade who responded to a combination therapy with docetaxel
and radiotherapy and a good treatment toleration, with only
grade 1 esophagitis recorded. Tumor regression was minimal
on CT scan; however, fluorodeoxyglucose positron emission
tomography, initially positive for tracer uptake in the tumor
mass, was negative after combination therapy. No evidence
of progression was documented after 12 months of follow-up.
Neoadjuvant chemotherapy with cytoreductive intent can be
pursued to facilitate cardiac surgery.56
Postoperative radiotherapy is an effective adjuvant to
complete excision for extracardiac soft tissue sarcomas.57 Its
value in the treatment of cardiac sarcomas is limited by the
sensitivity of the heart to radiation injury; in fact, exposure of
ventricular wall to a radical radiation dose can cause serious
cardiomyopathy and/or chronic pericarditis.42,58–62 There-
fore, the role of radiotherapy in the adjuvant setting or as
primary treatment is uncertain, because rarely used and only
anecdotal responses are reported.63,64 In one case, Movsas
et al.63 documented the complete response of an unresectable
high-grade sarcoma with hyperfractionated radiotherapy (to-
tal dose of 7050 centigrays) with concomitant administration
of iododeoxyuridine as radiosensitizer. Nevertheless, the
overall prognosis for primary cardiac sarcomas remains very
poor, with reported mean survival of 16.5 and 9.6 months in
two series of 24 and 17 cases, respectively.16,65
CONCLUSION
For their intrinsic rarity, diagnosis, classification, and
treatment of primary cardiac sarcomas are largely based on
their soft tissue counterparts. Additional studies, including
biomolecular and genetic characterization, are needed to
better define the origin and biology of these highly aggressive
tumors. Collection and analysis of larger series will amelio-
rate and better address therapeutic strategies to improve
prognosis of cardiac sarcomas.
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